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Objectives
1. Test combinatorial effects of each drug from the 
chemical screen with 3mM Temozolomide [a 
known effective concentration of Temozolomide]
2. Test the drug combinations for dose range and 
target specificity. Find out if Temozolomide plus a 
given drug act via the target pathways or other 
downstream effectors. 
3. Our studies in Drosophila are expected to 
generate insights on possible modes of action of 
validated drugs. 
4. Validated drugs will be tested in mammalian 
models (by our collaborators) for their efficacy and 
specificity to identify the candidate-drugs for 
further studies in clinical trials in the future.
Abstract
Today, there are over 250 drugs being used to cure 
over 100 different types of cancer, and one that might 
prove effective for a certain type of cancer might 
prove harmful or ineffective for another type. We plan 
to screen a chemical library of tyrosine kinase 
inhibitors to test their effects on glioma growth in a 
GAL4xUAS Drosophila glioma model. We first tested 
Temozolomide to establish proof of principle. Next, 
we compared this to a group of Tyrosine Kinase
inhibitors. We found both enhancers (positive 
regulators) that increase glioma growth, and 
repressors (negative regulators) that suppress the 
growth of the tumor through this screen. However, 
none of the drugs caused a significant suppression 
without unwanted lethality suggesting that a better 
approach is to use low doses of different drugs in 
combination rather than increase the dose of a single 
drug- which is likely responsible for lethal effects 
observed.
Glioma Progression
How Temozolomide Impacts
Temozolomide is a DNA alkylating agent that is 
being used in glioma treatment due to it leading to 
apoptosis 
Results
• Discovered that most effective concentration of 
Temozolomide was 3mM
Future Directions
• Continue chemical screen through Plate 1 (Drugs A-H).
• Test for combinatorial effects with Tyrosine Kinase 
Inhibitors determined in the Primary Drug Screen. 
• Test the drug combinations for dose range and target 
specificity.
• Use Western Blotting to determine Mode of Action 
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